Purpose: To explore the correlation between contrast‐enhancement patterns on dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) and angiogenesis by analyzing microvessel density (MVD), vascular endothelial growth factor (VEGF), and P53 protein expression in hepatocellular carcinoma (HCC). Material and Methods: MRI was performed with a GE Signa 1.5T MR scanner using SE and FMPSPGR sequences in 30 patients (38 lesions) during the period October 1998 to March 2000. All had histopathologically proven HCC. MR images were reviewed/analyzed retrospectively. The 30 patients were between 35 and 65 years of age (average age 58; 18 M and 12 F). SE T1WI, PDWI, and T2WI were acquired initially. The FMPSPGR sequence was acquired in the same position. The DCE‐MRI was performed in the arterial, portal vein, and delay phase after a bolus injection of Gd‐DTPA. The specimens were stained immunohistochemically for CD34, VEGF, and P53. MVD was highlighted by anti‐CD34 antibody staining. The enhancement features of HCC lesions were studied correlatively with the tumor MVD, VEGF, and P53 expression at protein level. Results: In the arterial phase, the results showed that MVD of HCC in the high‐enhancement group (229.76±80.96) was higher than that in the equal‐enhancement (173.09±61.38) and low‐enhancement groups (153.00±108.58) (P<0.01, respectively). VEGF expression of HCC in the high‐enhancement group (68.42%) was higher than that in the equal‐enhancement (36.36%) and low‐enhancement groups (38.89%) (P<0.05, respectively). In the portal vein phase, MVD of HCC in the enhancement group (259.80±93.30) was higher than that in the non‐enhancement group (178.64±92.65) (P<0.05). No significant correlation was found between VEGF expression and the enhancement feature in the portal vein phase. In the delay phase, MVD of HCC in the ring‐enhancement group (269.06±57.89) was significantly higher than that in the non‐ring‐enhancement group (144.10±88.90) (P<0.01). There was a significant difference in VEGF expression between the ring‐enhancement group (76.47%) and the non‐ring‐enhancement group (42.86%) (P<0.05). No significant correlation was detected between P53 protein expression and the enhancement feature. Relative enhancement (RE) correlated with MVD, but not with VEGF and P53 protein expression. Conclusion: The contrast‐enhancement patterns on DCE‐MRI are influenced by tumor angiogenesis, as reflected by elevated VEGF expression, and are therefore valuable indicators for accessing tumor angiogenic activity and tumor neovascularization in vivo in HCC patients.
[1]
M. Volm,et al.
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
,
1996,
British Journal of Cancer.
[2]
Lee Kt,et al.
Role of angiogenesis in hepatitis and hepatocellular carcinoma.
,
1999
.
[3]
L D Buadu,et al.
Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.
,
1996,
Radiology.
[4]
C. Angeletti,et al.
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.
,
1997,
British Journal of Cancer.
[5]
G Brix,et al.
Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement.
,
1997,
Cancer research.
[6]
Zeng-chen Ma,et al.
Microvessel density of hepatocellular carcinoma: its relationship with prognosis
,
1999,
Journal of Cancer Research and Clinical Oncology.
[7]
T. Mitsui,et al.
Quantitation of sinusoid‐like vessels in hepatocellular carcinoma: Its clinical and prognostic significance
,
1997,
Hepatology.
[8]
L. Ellis,et al.
p53, vessel count, and vascular endothelial growth factor expression in human colon cancer
,
1998,
International journal of cancer.
[9]
G Brix,et al.
Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival.
,
1998,
Cancer research.
[10]
Brygida Berse,et al.
Vascular permeability factor (VPF, VEGF) in tumor biology
,
1993,
Cancer and Metastasis Reviews.
[11]
T. Nabika,et al.
Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
,
1998,
Hepatology.
[12]
T. Nakajima,et al.
Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry.
,
2008,
Liver.